STAT+: A year after distressed buyout, what’s become of Bluebird Bio?

David Meek bought Bluebird Bio last year for the pharma industry equivalent of loose change.&#x A0; The company was on the brink of bankruptcy. In 12 months, he says, it’s been transformed.&#x A0; In a swaggering&#x A0; interview, one of the first he’s given since the deal, Meek lambasted competitors and claimed the company would dominate the market for sickle cell disease gene therapies for years to come. By 2030, he said the company — now rebranded as Genetix — would be treating 1,000 patients per year. Continue to STAT+ to read the full story…